Cathay Biotech (688065) 山西证券·2024-08-19 12:30Investment Rating - The report maintains an "Accumulate-B" rating for the company [1] Core Views - The company is expected to benefit from the increasing production of dodecanedioic acid, which is driving revenue growth. The collaboration in bio-based nylon is progressing smoothly [1][3] - The company has achieved significant sales in bio-based polyamide, with a current capacity of 100,000 tons and an additional 900,000 tons under construction [1] - The company reported a revenue of 14.44 billion yuan for the first half of 2024, a year-on-year increase of 40.16%, and a net profit of 2.47 billion yuan, up 2.31% year-on-year [2] Financial Performance Summary - The company forecasts revenues of 29.96 billion yuan, 48.25 billion yuan, and 76.49 billion yuan for 2024, 2025, and 2026 respectively, with year-on-year growth rates of 41.73%, 61.01%, and 58.54% [1] - The projected net profit for the same years is 5.14 billion yuan, 7.08 billion yuan, and 8.59 billion yuan, with corresponding year-on-year growth rates of 40.27%, 37.67%, and 21.33% [1] - The earnings per share (EPS) are expected to be 0.88 yuan, 1.21 yuan, and 1.47 yuan for 2024, 2025, and 2026, with price-to-earnings (PE) ratios of 40.84, 29.66, and 24.45 respectively [1] Market and Product Insights - The bio-based polyamide has applications in textiles, clothing, and engineering plastics, with a focus on energy-saving and emission-reduction advantages [1][3] - The company has established strategic partnerships to promote the use of bio-based materials in photovoltaic applications, aiming to replace aluminum frames with new materials [1]